These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.AB - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. 2016 Apr;14(4):389-400. doi: 10.6004/jnccn.2016.0046.Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.J Natl Compr Canc Netw. Maintenance therapy for multiple myeloma is a common clinical practice, but questions remain about which agent to … 2020 Jul 22;21(15):5192. doi: 10.3390/ijms21155192.Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S, Mailankody S, Shah U, Lesokhin A, Hassoun H, Tan C, Maura F, Derkacs A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetsky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O.medRxiv.



Clipboard, Search History, and several other advanced features are temporarily unavailable.



These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma. About NCCN Optimal Regimen in Maintenance Therapy for Multiple Myeloma Remains Unclear According to NCCN Expert.

The following new translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) are now available for free download: Spanish (Latin America) Hairy Cell Leukemia, Version 1.2020; Primary Cutaneous Lymphomas; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020; Multiple Myeloma, Version 2.2020 COVID-19 is an emerging, rapidly evolving situation.

Epub 2016 May 9.Blood Cancer J. Sheridan PubFactory Updates in Version 3.2020 of the NCCN Guidelines for Multiple Myeloma from Version 2.2020 include: MYEL-F 3 of 3: Isatuximab-irfc in combination with pomalidomide and dexamethasone was added under Other Recommended Regimens

By continuing you agree to the 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.J Natl Compr Canc Netw. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. View full fingerprint The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.T1 - Multiple myeloma, version 1.2020 featured updates to the NCCN guidelinesN2 - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. AB - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.UR - http://www.scopus.com/inward/record.url?scp=85072968604&partnerID=8YFLogxKUR - http://www.scopus.com/inward/citedby.url?scp=85072968604&partnerID=8YFLogxKJO - JNCCN Journal of the National Comprehensive Cancer NetworkJF - JNCCN Journal of the National Comprehensive Cancer Network"We use cookies to help provide and enhance our service and tailor content. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma. Overview. Reference Article: NCCN Guidelines Version 2.2020 Multiple Myeloma January 8, 2020 NCT04052880 : Clinical Trial: Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.